Swiss Startup Biocartis Targets Decentralized MDx Market | GenomeWeb

By Tony Fong

NEW YORK (GenomeWeb News) – Established diagnostics firms such as Roche and Abbott can have the batch processing market, as far as Biocartis is concerned. The Swiss-based start-up has its eyes on the decentralized molecular diagnostics space.

In February, Biocartis acquired Royal Philips Electronics' molecular diagnostic platform, and is now in the process of building it out in expectations of a late-2012 launch.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Through a transcriptome study, researchers home in on the activity of inflammation-linked genes in chronically lonely people.

Determining who is and is not an author and where a researcher should fall on a list of authors can be a tricky task, Nature News writes.

In PNAS this week: variant protective against Alzheimer's disease, effect of whole-genome duplication on methylation in rice, and more.

Genome editing is also bringing up questions when applied to farm animals, the New York Times reports.